微信内可能无法直接打开本站。请点右上角 ··· → 在浏览器打开，或复制链接。
STAT+: FDA approves Bristol multiple myeloma treatment, marking debut of novel drug class
RSS 官方收录 · 可信分层展示
关键摘要
The Food and Drug Administration on Thursday approved an oral treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of medicine for the blood cancer and the first drug cleared by U.…
- regulators using a more sensitive measure of remission.
- The Bristol drug, iberdomide, will be sold under the brand name Zenbex…
- It will be used in combination with two other drugs, Darzalex and dexa…
摘要引擎：抽取
正文提要
The Food and Drug Administration on Thursday approved an oral treatment for advanced multiple myeloma made by Bristol Myers Squibb, marking the debut of a new class of medicine for the blood cancer and the first drug cleared by U.S. regulators using a more sensitive measure of remission.
The Bristol drug, iberdomide, will be sold under the brand name Zenbexus. It will be used in combination with two other drugs, Darzalex and dexamethasone, to treat patients with multiple myeloma who have received at least one prior line of therapy.
“With the Zenbexus approval, Bristol is the first company to bring a novel class of drugs to patients with multiple myeloma, opening venues for many more potential combinations,” said Cristian Massacesi, Bristol’s chief medical officer, in an interview with STAT ahead of the approval announcement.